Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple mail delivery could boost colorectal cancer screening rates

NCT ID NCT05589675

Prevention Sponsor: International Agency for Research on Cancer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This trial tests whether sending a colorectal cancer screening kit directly to people's homes, along with the invitation letter, increases the number of people who get screened. It compares this approach to the standard practice of asking people to visit their doctor to receive the kit. The study involves over 71,000 adults aged 50-74 in France who are new to the national screening program. Some participants also receive a notification one month before the invitation to see if that further boosts participation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Home delivery of a fecal immunochemical test (FIT) kit, with or without a prior notification letter
What this could lead to
If mailing the screening kit directly to people's homes increases participation, it could lead to higher colorectal cancer detection rates and save lives through earlier treatment.
What could go wrong
The trial is large but only tests a delivery method, not a new treatment. Results may vary by region or population, and even with higher participation, some people may still not complete the test or follow up on positive results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

71,117 people

The number who actually took part.

Started

Apr 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women and men aged 50 to 74 years old * Living in the study area (Departments of Ardennes, Meurthe-et-Moselle, and Moselle, France) * At moderate risk of colorectal cancer, i.e. eligible to the organised programme and receiving the first invitation of the screening round (not a reminder letter) Exclusion Criteria: * Outside the target age (less than 50 years old, or 75 years and more) * Receiving the reminder letter * At high or very high risk of colorectal cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

Contacts and locations

Locations

  • Regional Cancer Screening Coordinating Centre, Ardennes site

    Charleville-Mézières, Ardennes, 08000, France

  • Regional Cancer Screening Coordinating Centre, Meurthe-et-Moselle Site

    Nancy, Meurthe-et-Moselle, 54500, France

  • Regional Cancer Screening Coordinating Centre, Moselle Site

    Metz, Moselle, 57000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.